Who
James Paul Rickey
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Braveheart Bio; Senior VP and CFO, Alpine Immune Sciences; VP, Finance and Administration, Immune Design.
In numbers
- Trades disclosed
- 77
- Buys
- 2
- Sells
- 12
- Bought
- $1.0M
- Sold
- $5.8M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 7 Jan 2015
- Last trade
- 7 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart BioBiotechnology | SEC FORM 4 Bought | $500K27,777 at $18.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart BioBiotechnology | SEC FORM 4 Bought | $500K27,777 at $18.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | BRVE Braveheart Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | BRVE Braveheart Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 20 May 2024filed 20 May 2024 | Alpine Immune Sciencesoption or derivative | SEC FORM 4 Code D | —836 | filing |
| 20 May 2024filed 20 May 2024 | Alpine Immune Sciencesoption or derivative | SEC FORM 4 Code D | —137 | filing |
| 20 May 2024filed 20 May 2024 | Alpine Immune Sciencesoption or derivative | SEC FORM 4 Code D | —143 | filing |
| 20 May 2024filed 20 May 2024 | Alpine Immune Sciencesoption or derivative | SEC FORM 4 Code D | —1,214 | filing |
| 20 May 2024filed 20 May 2024 | Alpine Immune Sciencesoption or derivative | SEC FORM 4 Code D | —112,945 | filing |
| 20 May 2024filed 20 May 2024 | Alpine Immune Sciencesoption or derivative | SEC FORM 4 Code D | —112,500 | filing |
| 20 May 2024filed 20 May 2024 | Alpine Immune Sciencesoption or derivative | SEC FORM 4 Code D | —108,999 | filing |
| 20 May 2024filed 20 May 2024 | Alpine Immune Sciencesoption or derivative | SEC FORM 4 Code D | —78,000 | filing |
| 20 May 2024filed 20 May 2024 | Alpine Immune Sciences | SEC FORM 4 Code D | —26,761 | filing |
| 20 May 2024filed 20 May 2024 | Alpine Immune Sciences | SEC FORM 4 Code D | —31,200 | filing |
| 7 May 2024filed 9 May 2024 | Alpine Immune Sciencesoption or derivative | SEC FORM 4 Code M | —1 at $0.00 | filing |
| 7 May 2024filed 9 May 2024 | Alpine Immune Sciencesoption or derivative | SEC FORM 4 Code M | —7,055 at $0.00 | filing |
| 7 May 2024filed 9 May 2024 | Alpine Immune Sciencesoption or derivative | SEC FORM 4 Code M | —857 at $0.00 | filing |
| 7 May 2024filed 9 May 2024 | Alpine Immune Sciencesoption or derivative | SEC FORM 4 Code M | —164 at $0.00 | filing |
| 7 May 2024filed 9 May 2024 | Alpine Immune Sciencesoption or derivative | SEC FORM 4 Code M | —18,286 at $0.00 | filing |
| 7 May 2024filed 9 May 2024 | Alpine Immune Sciencesoption or derivative | SEC FORM 4 Code M | —398 at $0.00 | filing |
News
Braveheart Bio (NASDAQ:BRVE) Stock Price Down 7.6% – Here's WhyBRVE · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name James Paul Rickey; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.